Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Why is it surprising when drug executives stay true to their word? And can neoantigen cancer vaccines work?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.
